BioMark Diagnostics Inc.
BUX
Rang in Aktien
#26716
BioMark Diagnostics Inc. is an oncology specialist, developing advanced... BioMark Diagnostics Inc. is an oncology specialist, developing advanced diagnostic tools for cancer to enable early detection, continuous patient monitoring, and the assessment of initial treatment efficacy. The firm holds a research partnership with the Icahn School of Medicine, collaborating on clinical trials specifically addressing the early identification of lung cancer. Founded in 2014, its corporate headquarters are situated in Richmond, Canada. BioMark Diagnostics Inc. operates as a subsidiary of Biomark Technologies Inc.
Aktienkurs
$0.33433516
Zuletzt synchronisiert: 2026-10-20
Marktkapitalisierung
$35.60M
Veränderung (1 Tag)
-3.08%
Veränderung (1 Jahr)
36.77%
Land
CA
Handel BioMark Diagnostics Inc. (BUX)
Kategorie
Healthcare
Kursverlauf für BioMark Diagnostics Inc. (BUX)
Höchster Schlusskurs: $0.38 am 2026-10-01
Niedrigster Schlusskurs: $0.35 am 2015-03-01
Niedrigster Schlusskurs: $0.35 am 2015-03-01
Kursverlauf der Aktie von BioMark Diagnostics Inc. von 2015 bis 2026
Jährliche Kursentwicklung
| Jahr | Leistung |
|---|---|
| 2026 (TTM) | 6.73% |
| 2025 | 136.71% |
| 2024 | -19.87% |
| 2023 | 29.58% |
| 2022 | -34.72% |
| 2021 | 122.09% |
| 2020 | -51.07% |
| 2019 | 376.19% |
| 2018 | -44.93% |
| 2017 | -9.77% |
| 2016 | -22.98% |
| 2015 | 0.00% |
Aktienkurs vergleichbarer Unternehmen oder Wettbewerber
| Unternehmen | Aktienkurs | Veränderung 1J% | Land |
|---|---|---|---|
| $694.53 | 24.47% |
US
|
|
| $234.00 | 5.99% |
US
|
|
| $416.01 | 122.61% |
US
|
|
| $22.06 | 54.01% |
CN
|
|
| $177.93 | 22.13% |
US
|
